RUDO MADONDO-GWITIRA: Open Payments
NPI 1396351474 · ARLINGTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,786 in 87 payments from 21 companies in 2025. Trend: 2023 $309 · 2024 $1,422 · 2025 $1,786
Food & beverage: $1,696Education: $90
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 12 | $226 |
| Astellas Pharma US Inc | 6 | $180 |
| GlaxoSmithKline, LLC. | 8 | $169 |
| AstraZeneca Pharmaceuticals LP | 8 | $168 |
| PFIZER INC. | 9 | $159 |
| Lilly USA, LLC | 9 | $154 |
| Eisai Inc. | 5 | $152 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $137 |
| Avvisto Therapeutics, LLC | 3 | $58 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $48 |
Products named: Leqembi, Kerendia, TRELEGY ELLIPTA, MOUNJARO, AIRSUPRA, Veozah, JARDIANCE, Ozempic.
Industry payments across TX — which companies pay providers there.
